Open AccessStructure‐Based Drug Design: Multi‐Arm PEG/Peptidomimetic Conjugate Inhibitors of DR6/APP Interaction Block Hematogenous Tumor Cell Extravasation (Adv. Sci. 11/2021)
Author(s) -
Wang Liting,
Shen Qing,
Liao Hongze,
Fu Hao,
Wang Qi,
Yu Jian,
Zhang Wei,
Chen Chuanrong,
Dong Yang,
Yang Xupeng,
Guo Qianqian,
Zhang Jiali,
Zhang Jian,
Zhang Wei,
Lin Houwen,
Duan Yourong
Publication year - 2021
Publication title -
advanced science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.388
H-Index - 100
ISSN - 2198-3844
DOI - 10.1002/advs.202170064
Subject(s) - peptidomimetic , extravasation , conjugate , peg ratio , medicine , pharmacology , drug , chemistry , necroptosis , cancer research , peptide , programmed cell death , biochemistry , pathology , apoptosis , mathematical analysis , mathematics , finance , economics
In article number 2003558 by Hongze Liao, Houwen Lin, Yourong Duan, and co‐workers, first class of APP/DR6 inhibitor, polymer–peptidomimetic PEG‐tAHP‐DRI, are developed by utilizing three rationaldesigned screening strategies, which demonstrate promising anti‐hematogenous metastatic activity by inhibiting the binding of amyloid precursor protein (APP) and death receptor 6 (DR6) as well as blocking the necroptosis of vascular endothelial cells induced by tumors cells.